Medicine and Dentistry
COVID-19
86%
Apixaban
82%
Blood Transfusion
64%
Rivaroxaban
62%
Blood Stasis
56%
Thrombosis
53%
Major Bleeding
47%
Heart Surgery
46%
Bleeding
44%
Blood Clotting Factor 10a Inhibitor
42%
Pathologist
40%
Von Willebrand Factor
40%
Transfusion Medicine
40%
Prothrombin Complex
40%
Platelet
39%
Severe Acute Respiratory Syndrome Coronavirus 2
36%
Receptor Binding
32%
Apheresis
28%
Anticoagulation
28%
Diseases
26%
Antithrombotic
26%
Direct Oral Anticoagulant
25%
Infection
25%
Coronavirinae
24%
Venous Thromboembolism
23%
Hypochromic Anemia
20%
Aptamer
20%
Sulfhemoglobinemia
20%
Erythrocyte Transfusion
20%
Health System
20%
Host Cell
20%
Biological Therapy
20%
Blood Culture
20%
Randomized Controlled Trial
20%
Acute Kidney Injury
20%
Ticagrelor
20%
Hemoglobin Determination
20%
Placenta Accreta
20%
Renal Replacement Therapy
20%
Plasma Exchange
20%
Angiotensin Converting Enzyme 2
20%
End Stage Renal Disease
20%
Hysterectomy
20%
Mixing Study
20%
Thrombophilia
20%
Fibrinogen Concentrate
19%
Partial Thromboplastin Time
16%
Thromboembolism
15%
Thrombocyte Transfusion
13%
Persistent Truncus Arteriosus
13%
Keyphrases
Hospitalized Patients
43%
Apixaban
43%
Therapeutic Apheresis
40%
Peripheral Venous Access
40%
Thrombosis
27%
Hemostasis
27%
Parenteral Anticoagulants
24%
Rivaroxaban
23%
Anti-Xa Level
22%
Factor Xa Inhibitors
22%
Major Bleeding
21%
Level Monitoring
20%
Tracking System
20%
Proficiency Testing
20%
Complex Cardiac Surgery
20%
Convalescent Plasma
20%
Anti-Xa
20%
College of American Pathologists
20%
Removal Time
20%
Apheresis Procedures
20%
Bamlanivimab
20%
Massive Blood Transfusion
20%
Carboxyhemoglobinemia
20%
CyaB
20%
Von Willebrand Factor
20%
Renal Replacement Therapy
20%
SARS-CoV-2 Spike Protein
20%
CoV-2
20%
Hemostasis Laboratory
20%
Ultrasound-based
20%
Academic Health System
20%
Andexanet Alfa
20%
Acute Kidney Injury
20%
End-stage Renal Disease
20%
Gp120
20%
Acid-base Homeostasis
20%
Total Processing Time
20%
Venous Thromboembolism
20%
Clinical Transfusion Medicine
20%
Factor Concentrates
20%
Selected Topic
20%
Direct Oral
20%
External Quality Assessment
20%
Fibrinogen Concentrate
14%
Casirivimab-imdevimab
13%
Package Labels
12%
DOAC Levels
11%
Inlet Flow Rate
10%
Peripheral Blood Stem Cell Collection
10%
Etesevimab
10%
Pharmacology, Toxicology and Pharmaceutical Science
Apixaban
100%
Rivaroxaban
80%
Diseases
71%
Coronavirinae
65%
Bleeding
45%
Infection
40%
Thrombosis
34%
Direct Oral Anticoagulant
25%
Blood Clotting Factor 10a Inhibitor
24%
Venous Thromboembolism
23%
Cohort Study
22%
SARS Coronavirus
21%
Adenylate Cyclase
20%
Replacement Therapy
20%
Receptor
20%
Placenta Accreta
20%
Neutropenia
20%
Randomized Clinical Trial
20%
Acute Kidney Failure
20%
Ticagrelor
20%
Aptamer
20%
Andexanet Alfa
20%
End Stage Renal Disease
20%
Angiotensin Converting Enzyme 2
20%
Neutrophilia
20%
Monoclonal Antibody
20%
Plasmodium falciparum
20%
Mortality Rate
16%
Thromboplastin
16%
Fibrinogen Concentrate
14%
Prothrombin
12%
Blood Stasis
11%
Dose-Response Study
10%
Thromboembolism
10%
Acetylsalicylic Acid
10%
Antiplatelet
9%
Retrospective Study
6%
Anticoagulant Agent
6%
Inflammation
6%
Sepsis
6%
Amphotericin B Deoxycholate
6%
Leukocytosis
6%
Antimalarial Agent
6%
Antimicrobial Agent
6%
Comorbidity
5%
Population Study
5%
Vitronectin
5%
Drug Concentration
5%
Virus Infection
5%
